Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021

Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes

Acorda Therapeutics Announces Corporate Restructuring, Management Changes

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2021 Results - Earnings Call Transcript

Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results

Acorda Therapeutics Reports Second Quarter 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know

Acorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years. The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket.

Acorda Therapeutics Continues To Maneuver For A Turnaround

The stock price of Acorda Therapeutics Inc (NASDAQ: ACOR) increased by over 40% pre-market. This is why it happened.

ACOR Stock Increases Over 40% Pre-Market: Why It Happened

Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in Spain.

Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med

The stock price of Acorda Therapeutics Inc (NASDAQ: ACOR) increased 24.67% after hours. This is why it happened.

ACOR Stock Increased 24.67% After Hours: Why It Happened

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Repayment of Convertible Senior Notes

Acorda Therapeutics Announces Repayment of Convertible Senior Notes

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2021 Financial Results

Acorda Therapeutics Reports First Quarter 2021 Financial Results

Acorda Therapeutics appears to be making moves to prepare for a potential turnaround in the coming years. I intend to discuss the company's prospects for a turnaround. The company sold some of their manufacturing operations which provided some cash and decreased INBRIJA's cost of goods. Now, the company has to secure an Ex-U.S. partnership and optimize ARCUS.

Acorda Therapeutics: Buying Before The Coast Is Clear

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

Acorda (ACOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy

ARDSLEY, N.Y.--(BUSINESS WIRE)--Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela”.

Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”

Is (ACOR) Outperforming Other Medical Stocks This Year?

Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2020 Results - Earnings Call Transcript

Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

News for Acorda Therapeutics Stock (ACOR)